UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~November~~February 2714, ~~2018~~2019

Spring Pharmaceutical Group, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-53600	30-0781441
(Commission File Number)	(IRS Employer Identification No.)

11 Quanxing Road

Sishui County, Shandong Province 273200

People's Republic of China

(Address of principal executive offices and zip code)

86-537-4268278

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 9.01 Exhibits.

Exhibit 99.1

Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Spring Pharmaceutical Group, Inc.

	Spring Pharmaceutical Group, Inc.


Dated: February 15, 2019	By: /s/ Tinghe Yan
	Tinghe Yan
	Chief Executive Officer

By: /s/ Tinghe Yan

Tinghe Yan

Chief Executive Officer

Dated: November 30, 2018

Filing Compare · SPRING PHARMACEUTICAL GROUP, INC.